MIRA Targets 2025 Efficacy for Novel Ketamine Analog in Neuropathic Pain Treatment

MIRA Pharmaceuticals, Inc., a preclinical-stage biotech firm, is making strides in the clinical development of its novel oral ketamine analog, Ketamir-2, aimed at treating neurologic and neuropsychiatric conditions such as neuropathic pain. The company announced its intention to demonstrate clinical efficacy as early as 2025, using innovative Phase I/II trial designs to accelerate drug approval timelines.

As part of this strategy, MIRA has initiated the development of Ketamir-2 in capsule form, partnering with Formulex, a leader in nano-tech drug delivery, to optimize bioavailability and ease of administration. The goal is to ensure that Ketamir-2 performs efficiently in upcoming clinical trials.

MIRA is on track to file an Investigational New Drug (IND) application with the FDA for Ketamir-2 in December 2024. In preparation, the company is advancing Good Laboratory Practice (GLP) toxicology studies and assembling data for regulatory submission.

To meet its ambitious 2025 efficacy goals, MIRA is emphasizing a strategic focus on detecting clinical activity in neuropathic pain through early human trials. The company is also conducting preclinical studies on diabetic and cancer-induced neuropathy, with results anticipated by the end of 2024. These findings will help refine the drug's target population and increase the chances of positive outcomes in human trials.

MIRA's Phase I clinical trial, set to begin in early 2025, will evaluate the safety, tolerability, and pharmacokinetics of Ketamir-2. This trial, in collaboration with top research institutions, marks a critical step in MIRA’s path to bring new treatment options to patients. MIRA is also exploring the potential use of Ketamir-2 in treating mental health disorders, including treatment-resistant depression, PTSD, and major depressive disorder with suicidal ideation.

CEO Erez Aminov expressed the company's commitment to fast-tracking development, aiming to position Ketamir-2 as a breakthrough treatment for neuropathic pain. Additionally, MIRA is planning to expand its therapeutic platform, potentially filing a new IND for depression-related conditions in the near future.

MIRA Pharmaceuticals holds the rights to Ketamir-2 in the U.S., Canada, and Mexico. The company's second major candidate, MIRA-55, is under investigation for anxiety and cognitive decline linked to early-stage dementia. If approved, MIRA-55 could represent a significant step forward in the treatment of various neurological disorders. Both Ketamir-2 and MIRA-55 have been cleared by the U.S. Drug Enforcement Administration (DEA) as non-controlled substances.